March 3, 2017 06:18 AM EST
Pharma

Sanofi steps up with a $645M deal to part­ner with As­traZeneca on a late-stage RSV an­ti­body

Arsalan Arif

Founder

Point­ing di­rect­ly at a piv­otal Phase III pro­gram, As­traZeneca has de­cid­ed to part­ner with Sanofi on an ex­per­i­men­tal an­ti­body for RSV.

The French phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Biotech seed rounds sink to low­est lev­el in years as in­dus­try slump drags on

Sanofi to pay $125M up­front for two im­munol­o­gy drugs from lit­tle-known biotech

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

Trump pledges his sup­port for a change to the IRA long sought by drug­mak­ers

US drugs re­ly heav­i­ly on in­gre­di­ents made over­seas, new re­port shows

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times